Abstract 5669
Background
The EGFR inhibitors cetuximab and panitumumab are indicated for patients suffering from metastatic colorectal cancer (mCRC), which are RAS wildtype. The aim of this analysis is to verify with real-world data whether the drug usage of those EGFR inhibitors reflects clinical guidelines with regards to their genomic profile.
Methods
Anonymized patients-level data collected through a large web-based survey between April 2017 and March 2018 was used. The study reported patient case history information across all cancer types in 5EU (France, Germany, Italy, Spain & UK). Treatment information and biomarker testing information on 5248 mCRC drug treated patients were analyzed.
Results
Evaluating KRAS and NRAS biomarkers status, real-world data analysis showed that 18,9% of mCRC patients were not tested for N-RAS mutation and 11,4% were not tested for K-RAS mutation. 16% of the mCRC population were RAS mutant. However, 3,2% of these patients received cetuximab and panitumumab even though they did not qualify for this treatment, due to their RAS mutation. Among all mCRC patients who were RAS wildtype, 49,4% of them received cetuximab or panitumumab.
Conclusions
This analysis of real-word data showed that biomarkers testing is not carried out in all mCRC patients. Secondly, the use of EGFR inhibitors in the RAS mutant mCRC patient population demonstrates a misalignment with clinical guidelines. Howver, most of patients receiving EGFR inhibitors are RAS wildtype, which implies that the majority of mCRC patients receiving EGFR inhibitors is treated according to medical guidelines regarding their genomic profile.
Clinical trial identification
Legal entity responsible for the study
IQVIA Commercial GmbH & Co. OHG.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
L. Hoyer, N. Schmidt: Employee of IQVIA Commercial GmbH & Co. OHG.